1. Scrip
  2. >>Business
  3. >>Financing

Catalan Biotechs Boosted By International Backers

 
• By Kevin Grogan

The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.

HumanTower
Building a stable bioregion around Barcelona • Source: Shutterstock

Catalonia’s biotech sector has continued to boom despite the political storms that struck the region and the rest of Spain just over a year ago and foreign and domestic investment is on the rise.

Biocat, the agency that coordinates and promotes the health care and life sciences sector in Catalonia, has recently published a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Former Moderna Exec Launches Company Focused On mRNA Despite HHS Funding Cuts

 
• By David Wild

Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Finance Watch: CSL Restructuring Brings 15% Workforce Reduction, Vaccines Group Spinout

 
• By Mandy Jackson

Restructuring Edition: CSL Group will spin out CSL Seqirus as a standalone vaccines business as the parent company slims down. Some struggling companies are turning to investing in cryptocurrencies to create shareholder value.

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

 
• By Mandy Jackson

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead

 
• By Mandy Jackson

Sarepta is in a cash crunch with sales of Elevidys slumping due to safety concerns and with financial commitments coming due, including debt repayments and milestone fees for its partner Arrowhead.

More from Business

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By Mandy Jackson

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.